Can we manage prophylactic therapy in COVID-19 patients to prevent severe illness complications?

Abstract

Many patients with COVID-19 have thromboembolic complications that worsen their prognosis. Herein, the authors propose a modified version of the CHA₂DS₂-VASc score, including 1 point for COVID-19, so that prophylaxis to protect against thromboembolic events would be indicated before the condition becomes severe. The advantages of this modification would be prevention of the patient’s condition worsening due to thromboembolic problems and reduction of the likelihood of a need for intensive care and mechanical ventilation, reducing mortality.

Keywords:
COVID-19; coronavirus; anticoagulants; thrombosis; prevention; hospital mortality